News

March 13, 2010

03:43
Orexigen® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc. , a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release /bupropion HCL SR) as well as development of future formulations of Orexigen products.  The financial terms of the deal were not disclosed.

March 12, 2010

16:15
Orexigen® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc. , a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release /bupropion HCL SR) as well as development of future formulations of Orexigen products.  The financial terms of the deal were not disclosed.
Showing 1 - 20 of thousands.
Next › Last »